KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.95

Early palliative care for patients with glioblastoma: A randomized phase III clinical trial (EPCOG).

Heidrun Golla, Charlotte Nettekoven, Martin Hellmich, Iris Appelmann, Claudia Bausewein, Gerhild Becker, Christopher Boehlke, Tzvetina Brumbarova, Daniele Civello, Hans Clusmann, Birgit Haberland, Dieter Henrik Heiland, Ulrich Herrlinger, Birgit Jaspers, Melanie Joshi, Dirk Mülller, Wiebke Müller, Chuh-Hyoun Na, Martin Neukirchen, Lukas Radbruch, Marion Rapp, Roman Rolke, Maximilian Ruge, Michael Sabel, Oliver Schnell, Jacqueline Schwartz, Niklas Thon, Hartmut Vatter, Louisa von Baumgarten, Raymond Voltz, Roland Goldbrunner, EPCOG Study Group

Neuro Oncol 28(1) 226-240

PMID41071052
PMCIDPMC12962646
DOI10.1093/neuonc/noaf230
发表日期2025-10-10
入排依据:The study is a Phase III randomized trial in glioblastoma (oncology, human), but it fails two key eligibility criteria: 1) The primary endpoint is quality-of-life (FACT-Br), not a time-to-event efficacy endpoint. 2) The intervention is early palliative care (non-drug), not a drug-containing regimen. Therefore, it is not eligible for the oncology KM digitization cohort.
摘要

摘要

BACKGROUND: Positive effects of early integration of palliative care (EIPC) have been shown for systemic solid malignant tumors. We tested the hypothesis that EIPC improves quality of life (QoL), palliative care (PC) problems and mood in glioblastoma patients and reduces caregiver burden. METHODS: This randomized, rater-blinded, controlled trial conducted in six German university medical centers included glioblastoma patients within four weeks after diagnosis (first/recurrent) and their caregivers. Patients received standard care (control) or standard care and EIPC (intervention) for 12 months. Primary outcome was change in QoL after six months measured by the trial outcome index of the FACT-Br. Data were assessed 3-monthly for up to 24 months. RESULTS: Between 05/2019 and 04/2021 patients were enrolled and randomized to the intervention (n = 109) or control group (n = 108). QoL at month six was in favor of the intervention, however not statistically significant (mean difference 4.1 with 95% CI, -4.4 to 12.6, P = .34; intervention: n = 98 (m = 54/f = 44); control: n = 89 (m = 50/f = 39)). In an analysis adjusted for time of death, performed because of a significant survival difference (control superior to intervention, P = .018), QoL was better in the intervention group (P = .041). Secondary outcomes showed that patients significantly benefited from EIPC regarding PC problems and mood especially after intervention ended, while caregivers did not seem to benefit. CONCLUSIONS: Provided that the survival difference is included in the analysis, EIPC improves QoL in glioblastoma patients. This, in addition to improved mood and PC problems, demonstrates that EIPC sustainably improves 'how to live' but not 'length of life'.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 2

Figure 2. Kaplan-Meier estimates of cumulative overall survival according to treatment group (modified intention-to-treat (mITT) population). Solid line = intervention group, dotted line = control group; HR = hazard ratio.

overall_survival

overall survival

Figure 2 · Panel overall_survival

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel overall_survival 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:off origin start
查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Trial profile (mITT), primary endpoint (after 6 months). MoCA = Montreal Cognitive Assessment, OSTC = optimized standard care, control group, PC = palliative care, OSTC+PC= intervention group; miTT (modified intention-to-treat): all patients randomized with a valid FACT-Br assessment at baseline and at least one further valid FACT-Br assessment.
非 KM Figure
Figure 3Figure 3. Change in the Trial Outcome Index (TOI) of the Functional Assessment of Cancer Therapy-Brain (FACT-Br) from baseline (EMM with 95% CI). Change = post value (month 3-24) minus baseline value. Higher scores indicating better QoL with respect to physical, functional and brain specific factors; range of TOI 0-148. Solid line: intervention, dotted line: control, EMM = estimated marginal mean, CI = confidence interval.
非 KM Figure
Figure 4Figure 4. Forest plot of subgroup results for the primary outcome measure ‘Trial Outcome Index’ (TOI) with interaction tests. CI = confidence interval; EMM = estimated marginal mean; SD = standard deviation.
非 KM Figure